Nicholas Kerton
Directeur/Membre du Conseil chez Queens Copse Management Ltd.
Profil
Nicholas Anthony Kerton currently works at Queens Copse Management Ltd., as Director and Actionreaction Ltd., as Director.
Dr. Kerton also formerly worked at Cambridge Cognition Ltd., as Chief Executive Officer & Director, Maybridge Chemical Holdings Ltd., as Chief Executive Officer, Sirigen Group Ltd., as Chief Executive Officer & Director in 2012, Lab 21 Ltd., as Non-Executive Chairman, Malthus Instruments Ltd, as Managing Director, Whatman, as Director-International Marketing, Cambridge Cognition Holdings Plc, as Non-Executive Director from 2016 to 2019, EIDP, Inc., as Principal, Celsis International Ltd., as Principal, and Wellcome Foundation Ltd, as Principal.
Dr. Kerton received his doctorate degree from The University of Nottingham.
Postes actifs de Nicholas Kerton
| Sociétés | Poste | Début |
|---|---|---|
| Queens Copse Management Ltd. | Directeur/Membre du Conseil | - |
| Actionreaction Ltd. | Directeur/Membre du Conseil | - |
Anciens postes connus de Nicholas Kerton
| Sociétés | Poste | Fin |
|---|---|---|
| CAMBRIDGE COGNITION HOLDINGS PLC | Directeur Général | 15/02/2016 |
Sirigen Group Ltd.
 Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | President | 01/08/2012 |
Cambridge Cognition Ltd.
 Cambridge Cognition Ltd. Packaged SoftwareTechnology Services Cambridge Cognition Ltd. operates as a neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. It offers CANTAB Tests and Services, CANTAB mobile and CANTABeclipse. The company was founded in 2002 and is headquartered in Cambridge, GB. | Directeur Général | - |
Lab 21 Ltd.
 Lab 21 Ltd. Medical/Nursing ServicesHealth Services Lab 21 Ltd. operates as a healthcare diagnostics company. It specializes in providing patients, doctors, hospitals ,and healthcare providers with diagnostic information for disease identification, disease predisposition, and personalized medicine, to help in managing health problems. It also offers diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. The company was founded in April 2005 by Berwyn E. Clarke and is headquartered in Cambridge, the United Kingdom. | Président | - |
| E I DU PONT DE NEMOURS AND CO | Corporate Officer/Principal | - |
Formation de Nicholas Kerton
| The University of Nottingham | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| CAMBRIDGE COGNITION HOLDINGS PLC | Technology Services |
| Entreprise privées | 11 |
|---|---|
Sirigen Group Ltd.
Sirigen Group Ltd. Chemicals: Major DiversifiedProcess Industries Harnessing the power of novel light-harvesting polymeric materials, Sirigen's amplification technology offers High Sensitivity Fluorescence™ (HSF™) detection to the Diagnostic and Life Science marketplaces. The company's versatile and HSF™ technology simplifies sample processing and instrumentation requirements in both immunodiagnostic and nucleic acid based applications, and facilitates high volume screening in theradiagnostics and other personal care applications. Its platform agnostic, enabling technology represents a quantum leap in detection capabilities, amplifying the sensitivity of a wide range of existing instrumentation and detection platforms by up to 100 fold. The company's technology is applicable to a diverse cross section of the biomedical industry including the $6billion drug discovery industry which can use it to test the efficacy of new drugs, the $12billion life sciences industry which can use Sirigen to develop new detection platforms, and the $35billion diagnostics industry, which can work with the company to optimise existing diagnostic techniques and to develop the next generation of diagnostic tools. Indeed the potential to deliver real time testing on miniaturised monitoring devices is close to reality. | Process Industries |
Whatman
 Whatman Industrial MachineryProducer Manufacturing Part of Danaher Corp., Whatman develops, manufactures, and markets separation technology used for filtration, purification, and storage of chemicals and other liquids and samples. The company is based in Maidstone, UK. | Producer Manufacturing |
Malthus Instruments Ltd
 Malthus Instruments Ltd Electronic Equipment/InstrumentsElectronic Technology Part of Malthus Instruments Ltd. management, Malthus Instruments is a British company that manufactures measuring devices. The company is based in Chester, UK. Malthus Instruments was acquired by Malthus Instruments. management on May 01, 1994. | Electronic Technology |
Celsis International Ltd.
 Celsis International Ltd. Medical SpecialtiesHealth Technology Celsis International Ltd. develops and supplies medical diagnostic products and laboratory services. The company was founded by Sir Christopher Evans in 1992 and is headquartered in Westminster, the United Kingdom. | Health Technology |
Maybridge Chemical Holdings Ltd.
 Maybridge Chemical Holdings Ltd. Pharmaceuticals: OtherHealth Technology Part of Thermo Fisher Scientific, Inc., Maybridge Chemical Holdings Ltd. provides organic compounds and combinatorial libraries for use in drug discovery. The company is based in Tintagel, UK. Maybridge Chemical Holdings was acquired by Fisher Scientific International, Inc. on November 18, 2002. | Health Technology |
| Wellcome Foundation Ltd | Commercial Services |
EIDP, Inc.
 EIDP, Inc. Chemicals: AgriculturalProcess Industries EIDP, Inc. engages in the provision of science-based products and services. It operates through the Seed and Crop Protection segments. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms around the world. The Crop Protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The company was founded by Eleuthere Irenee du Pont in 1802 and is headquartered in Indianapolis, IN. | Process Industries |
Lab 21 Ltd.
Lab 21 Ltd. Medical/Nursing ServicesHealth Services Lab 21 Ltd. operates as a healthcare diagnostics company. It specializes in providing patients, doctors, hospitals ,and healthcare providers with diagnostic information for disease identification, disease predisposition, and personalized medicine, to help in managing health problems. It also offers diagnostic products and services and supports blood bank screening, medical diagnostics, and drug discovery. The company was founded in April 2005 by Berwyn E. Clarke and is headquartered in Cambridge, the United Kingdom. | Health Services |
| Queens Copse Management Ltd. | |
| Actionreaction Ltd. | |
Cambridge Cognition Ltd.
Cambridge Cognition Ltd. Packaged SoftwareTechnology Services Cambridge Cognition Ltd. operates as a neuroscience technology company delivering near-patient assessment solutions to improve the understanding, diagnosis and treatment of neurological and psychiatric disorders. It offers CANTAB Tests and Services, CANTAB mobile and CANTABeclipse. The company was founded in 2002 and is headquartered in Cambridge, GB. | Technology Services |
